Yalçın, ŞuayıbDane, FaysalÖksüzoğlu, BernaÖzdemir, Nuriye YıldırımÖzkan, MetinDemirağ, Güzin GönüllüCoşkun, Hasan ŞenolKarabulut, BülentUstaoglu, Mehmet AliÖzdemir, FeyyazTurna, HandeYavuzşen, TuğbaAykan, FarukSevinç, AlperAkbulut, HakanYüce, DenizHayran, MutluKılıçkap, Saadettin2024-02-192024-02-192020-03-30Yalçın, Ş. vd. (2020). "Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study". BMC Cancer, 20(1).1471-2407https://bmccancer.biomedcentral.com/articles/10.1186/s12885-020-06758-9https://hdl.handle.net/11452/39848BackgroundCombination of gemcitabine and nab-paclitaxel has superior clinical efficacy than gemcitabine alone. Nevertheless, health-related quality of life. (QoL) associated with this combination therapy when administered at first-line in advanced pancreatic adenocarcinoma is unknown.MethodsA total of 125 patients were randomized to combination therapy (1000mg/m2 gemcitabine +125mg/m2 nab-paclitaxel) and single-agent gemcitabine (1000mg/m2) arms to take treatment weekly for 7 of 8weeks, and following 3 of 4weeks, until progression or severe toxicity. Primary endpoints were three-months of definitive deterioration free percent of patients, and QoL.ResultsOverall QoL analyses showed that 34 and 58.3% of cases in gemcitabine and gemcitabine+nab-P arms had no deterioration in 3rd month QoL scores (p=0.018). These proportions were 27.3 and 36.6% in 6(th) month assessments, respectively (p=0.357). Median overall survivals in combination and single-agent arms were 9.92months and 5.95months, respectively (HR: 0.64, 95% CI: 0.42-0.86, p=0.038). Median progression free survivals in these treatment arms were 6.28 and 3.22months, respectively (HR: 0.58, 95% CI: 0.39-0.87, p=0.008). Median time-to-deterioration were 5.36 vs 3.68months, and objective response rates were 37.1% vs 23.7% (p=0.009), respectively in combination and single-agent arms.ConclusionsCombination therapy with gemcitabine + nab-paclitaxel had better overall and progression-free survival than gemcitabine alone. Also, combination therapy showed increased response rate without toxicity or deteriorated QoL. Combination treatment with gemcitabine and nab-paclitaxel may provide significant benefit for advanced pancreatic cancer.Trial registrationThis study has been registered in ClinicalTrials.gov as NCT03807999 on January 8, 2019 (retrospectively registered).eninfo:eu-repo/semantics/closedAccessNab-paclitaxelMetastaticGemcitabinePancreatic cancerQuality of lifeCancerFolforinoxTrialOncologyAdenocarcinomaAdultAgedAlbuminsDeoxycytidineDrug therapy, combinationFemaleHumansMaleMiddle agedNeoplasm metastasisNeoplasm stagingPaclitaxelPancreatic neoplasmsQuality of lifeSurvival analysisArticle0005245021000042-s2.0-8508279266920132228512https://doi.org/10.1186/s12885-020-06758-9OncologyPancreas Adenocarcinoma; Gemcitabine; Pancreatic NeoplasmsGemcitabinePaclitaxel130-nm albumin-bound paclitaxelAlbuminoidDeoxycytidineGemcitabinePaclitaxelAdultAdvanced cancerAgedArticleCancer combination chemotherapyCancer localizationCancer survivalClinical effectivenessConstipationControlled studyDeteriorationDiarrheaDisease severityDrug efficacyDrug responseDyspneaFatigueFemaleHumanInsomniaLoss of appetiteMajor clinical studyMaleNausea and vomitingOverall survivalPainPancreas adenocarcinomaPancreas metastasisPhase 2 clinical trialProgression free survivalQuality of lifeRandomized controlled trialTreatment durationTreatment outcomeTreatment planningAdenocarcinomaCancer stagingClinical trialCombination drug therapyMetastasisMiddle agedMortalityPancreas tumorQuality of lifeSurvival analysis